A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer.
about
Epigenetic treatment of solid tumours: a review of clinical trialsDNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.Vorinostat in solid and hematologic malignanciesPhase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer.Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis.HDAC inhibition decreases the expression of EGFR in colorectal cancer cells.A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors.Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase.Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies.Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects.Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosisA phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors.Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid MalignanciesRecently identified and potential targets for colon cancer treatment.Romidepsin: a novel histone deacetylase inhibitor for cancer.Targeting histone deacetylases: development of vorinostat for the treatment of cancer.Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer.Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor.Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer.Effect of small interfering RNA 3'-end overhangs on chemosensitivity to thymidylate synthase inhibitors.Vorinostat-eluting poly(DL-lactide-co-glycolide) nanofiber-coated stent for inhibition of cholangiocarcinoma cells.Vorinostat enhances the anticancer effect of oxaliplatin on hepatocellular carcinoma cells.Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
P2860
Q26773803-991E8EC7-17DF-438D-A297-5B34CE249AB9Q30931932-777945D3-6E84-4171-BAE7-CB1A9B44CF24Q33385544-11BFCA0D-F503-4ECE-9E62-F7F3F421C4C1Q33391851-E7D789D3-EFC5-4266-B066-ABAB86625AC0Q33408000-2FDEBEA6-568B-430C-B9C8-512D081C58C3Q33432199-DC5F2AFA-BDCF-4847-B329-B3DD6B263702Q33862612-89035821-DFC7-4B0C-9223-6DB2102C98DEQ34099365-E4CEBB17-238D-4731-A198-AEDBE9FA25A8Q34363544-4D8ED7EA-CF51-45C1-9BD5-C60C35DB31EBQ34399444-CE9D7270-7CDD-493F-A4A9-13433A478299Q34488424-C41825E8-551C-4410-BA35-83687909B938Q35008045-01FAF66D-B29F-4BEA-BB78-9F0A2F865142Q35939690-7707E9D3-BB9A-4339-BB52-81B61937686BQ36084498-9D33CD5A-FFBF-4C34-B96C-4BD39C8EB11FQ36534059-1DF1C8D5-1BB9-4D2D-9A2B-8EB0EF8EDB3EQ36660672-8E78B50B-D025-4332-9DEF-5C7A65C21504Q37190106-49783AAD-DEA2-453D-88BA-78ED14320BC0Q37226511-A8933E5D-9ED2-4378-B679-E9CBAB9DA6B5Q37763104-FF324387-B3B7-477B-8CE8-1F93933E5EF8Q37893664-7E489665-C007-4D0E-AC12-BFE2F58FAF54Q37961738-26AB7A3B-73E4-4F42-B876-624C9410BE63Q38002127-04C95AAC-A3D2-41D3-AA1D-931AF9CD9D1FQ38118900-9E598150-95B9-47DE-B6A8-8045F07C2BC6Q38204673-1D8C9F00-0465-447A-87CE-DB9C83F5DE3BQ39214195-F0BE69DD-2B5A-45BF-A094-E794840F340CQ42211322-00D9F5FB-08D4-4CC9-A5A0-F4D10092E676Q47101153-14A61FD5-210B-4C70-B1F1-928BAFB5235BQ48119543-A36D4C63-1D1A-4A3C-9182-8F57CE02DBA9Q55447998-1DE621DD-AA5B-415A-AA3E-69B60ACF9C7A
P2860
A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer.
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A phase I, pharmacokinetic and ...... refractory colorectal cancer.
@ast
A phase I, pharmacokinetic and ...... refractory colorectal cancer.
@en
type
label
A phase I, pharmacokinetic and ...... refractory colorectal cancer.
@ast
A phase I, pharmacokinetic and ...... refractory colorectal cancer.
@en
prefLabel
A phase I, pharmacokinetic and ...... refractory colorectal cancer.
@ast
A phase I, pharmacokinetic and ...... refractory colorectal cancer.
@en
P2093
P2860
P1476
A phase I, pharmacokinetic and ...... refractory colorectal cancer.
@en
P2093
Alan Litwin
Gerald Fetterly
Igor Espinoza-Delgado
James A Zwiebel
Julianne L Holleran
Karoli Toth
Lakshmi Pendyala
Marwan G Fakih
Mary Ellen Ross
Merrill J Egorin
P2860
P304
P356
10.1158/1078-0432.CCR-08-2999
P407
P577
2009-04-21T00:00:00Z